Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02555761
Other study ID # 229666-007
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 19, 2015
Est. completion date March 19, 2018

Study information

Verified date July 2019
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.


Recruitment information / eligibility

Status Completed
Enrollment 3423
Est. completion date March 19, 2018
Est. primary completion date March 19, 2018
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria:

-Patients with itching associated with allergic conjunctivitis.

Exclusion Criteria:

-Patients with hypersensitivity to Lastacaft® or its components.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Alcaftadine Ophthalmic Solution 0.25%
Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.

Locations

Country Name City State
Korea, Republic of Barun Sungmo Eye Clinic Busan
Korea, Republic of chamjoeun Ophthalmic Clinic Busan
Korea, Republic of Daeyeon St.mary's Eye Center Busan
Korea, Republic of Dong-A University Hospital Busan
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of Inje University Haeundae Paik Hospital Busan
Korea, Republic of Pusan National University Hospital Busan
Korea, Republic of Pusan National University Yangsan Hospital Busan
Korea, Republic of Saint Mary Bright Eye Clinic Busan
Korea, Republic of Seo-myeon St.Mary's Hospital Busan
Korea, Republic of SeoMyeon St. Eye Clinic Busan
Korea, Republic of Soojung Eye Hospital Busan
Korea, Republic of Soonchunhyang University Cheonan Hospital Chungcheongnam-do
Korea, Republic of Cheil eye hospital Daegu
Korea, Republic of Daegu Nune Eye Hospital Daegu
Korea, Republic of Keimyung University Dongsan Medical Center Daegu
Korea, Republic of Kyoungpook national university hospital Daegu
Korea, Republic of Chonnam National University Hospital Daejeon
Korea, Republic of Clean Eye clinic Daejeon
Korea, Republic of Eye Love Eye Center Daejeon
Korea, Republic of Jungbuwoorieye Clinic Daejeon
Korea, Republic of Saebom Eye Clinic Daejeon
Korea, Republic of Chonnam National University Hospital Daejoen
Korea, Republic of Konyang University Hospital Daejoen
Korea, Republic of Konyang University Hospital Daejon
Korea, Republic of St. Mary's Eye center Geyonggi-do
Korea, Republic of Eins Eye Clinic Geyonsangnam-do
Korea, Republic of Bora Eye Clinic Gwangju
Korea, Republic of Bora Eye Clinic Gwangju
Korea, Republic of Gwang Ju Eye Clinic Gwangju
Korea, Republic of Happ Eye 21 Gwangju
Korea, Republic of Ansan Yonsei Eye Center Gyeonggi-do
Korea, Republic of Anyang Seoul Eye Clinic Gyeonggi-do
Korea, Republic of Bright eye Gyeonggi-do
Korea, Republic of Eagle Eye Center Gyeonggi-do
Korea, Republic of Munsan Jeil Eye Clinic Gyeonggi-do
Korea, Republic of Myongji Hospital Gyeonggi-do
Korea, Republic of Noon-Sarang Eye Hospital Gyeonggi-do
Korea, Republic of Seoul Shinsegae Eye Center Gyeonggi-do
Korea, Republic of Yonsei Dream Eye Clinic Gyeonggi-do
Korea, Republic of Bright Kim's Eye Clinic Gyeongsangnam-do
Korea, Republic of Fatima ophthalmology Gyeongsangnam-do
Korea, Republic of Gowoon eye clinic Gyeongsangnam-do
Korea, Republic of Sungmo Eye Hospital Haeundae-gu
Korea, Republic of Bupyung ST.Mary's eye clinic Incheon
Korea, Republic of Gachon University Gil Medical Center Incheon
Korea, Republic of Hangil Eye Hospital Incheon
Korea, Republic of Hangil Eye Hospital Incheon
Korea, Republic of Renessance eye center Incheon
Korea, Republic of Onuri Eye Hospital Jeollabuk-do
Korea, Republic of Pureun Eye Center Jeollabuk-do
Korea, Republic of Pureun Eye Center Jeollabuk-do
Korea, Republic of Seoul Eye Clinic Jeollanam-do
Korea, Republic of National Health Insurance Service Ilsan Hospital Kyounggi-do
Korea, Republic of Apgujeong Eye Center Seoul
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Bright Seoul Ophthalmology Seoul
Korea, Republic of Central seoul eye center Seoul
Korea, Republic of Gangnam ST. Mary's Eye Center Seoul
Korea, Republic of GS eye clinic Seoul
Korea, Republic of Hplus Eye Center Seoul
Korea, Republic of Ian Eye Center Seoul
Korea, Republic of Joeunnun Vision Clinic Seoul
Korea, Republic of Kim's Eye Hospital Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Lee Eye Institute Seoul
Korea, Republic of Lee, Im-sun Eye Clinic Seoul
Korea, Republic of Nune Eye Hospital Seoul
Korea, Republic of Park Chang Soo Eye Clinic Seoul
Korea, Republic of Saevit Eye Center Seoul
Korea, Republic of Samsung medical center Seoul
Korea, Republic of See Samsung Eye Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital Seoul
Korea, Republic of Sinchon Yeonsei Eye Hospital Seoul
Korea, Republic of Su Yonsei Eye Clinic Seoul
Korea, Republic of The catholic university of korea Seoul ST. Mary's Hospital Seoul
Korea, Republic of The Catholic Unoveristy of Korea, Seoul St Mary's Hospital Seoul
Korea, Republic of Yonsei Eye Clinic Seoul
Korea, Republic of Yonsei Woori Eye Clinic Seoul
Korea, Republic of Yoon Ho Eye Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Adverse Events 2 Weeks
See also
  Status Clinical Trial Phase
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT01470118 - A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase 4
Completed NCT03709121 - A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber Phase 1/Phase 2
Completed NCT01732757 - A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Phase 4
Recruiting NCT04299399 - Corneal Biomechanical Changes of Allergic Conjunctivitis
Completed NCT00917488 - Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP). Phase 2
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A
Completed NCT02082262 - AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Phase 3
Withdrawn NCT01541904 - Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis Phase 2
Completed NCT00311844 - A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Phase 4
Completed NCT02161146 - AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase 3
Completed NCT00718744 - Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units Phase 2
Recruiting NCT03186755 - Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Phase 4
Completed NCT01987765 - Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea N/A
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT01289431 - Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis Phase 2
Completed NCT00655109 - A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Phase 4
Completed NCT00424398 - Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Phase 2/Phase 3
Completed NCT03012165 - A Study of ADX-102 in Subjects With Allergic Conjunctivitis Phase 2

External Links